Morgan Stanley: China healthcare sector dips 1.3% amid licensing scrutiny By Investing.com

China’s healthcare sector fell 1.3% this week and is down 8.1% year to date as regulators in the U.S. and China increased scrutiny of biotech licensing and online prescription drug sales. Sentiment was also pressured by proposed U.S. COINS Act provisions that could restrict investments in Chinese biotech, although deal activity remained strong: Innovent and Pfizer announced a $10.5 billion oncology collaboration and WuXi Bio secured a five-year supply contract with Viridian Therapeutics. Hengrui’s HRS-7535 also showed up to a 1.68% HbA1c reduction at week 32 in phase III.

Analysis

The signal here is not a broad biotech rerating; it is a bifurcation between platform/supply-chain winners and single-asset or policy-sensitive names. CDMOs and manufacturers with China execution capacity gain relative value because every incremental licensing deal and cross-border program pushes more complexity into outsourced development, regulatory, and supply infrastructure. By contrast, innovation-heavy biotechs with meaningful China capital dependence face a slower multiple grind lower as U.S. screening risk raises the cost of capital and lengthens deal timelines.

The larger second-order effect is that licensing becomes more valuable than outright M&A. If U.S. investors and corporates face more review friction, Chinese companies can still monetize pipelines through regional or asset-level deals, but they may have to trade economics for speed and certainty. That benefits the few buyers with existing operating footprints and balance-sheet capacity, while smaller peers get forced into less favorable structures or delayed financings over the next 1-3 quarters.

The catalyst stack is asymmetric: ASCO can support sentiment for program-specific winners over days, but the regulatory overhang is a months-long multiple cap unless there is explicit carve-out language or enforcement proves toothless. The contrarian view is that the market may be over-penalizing China biopharma breadth while underpricing the durability of ex-China commercialization leverage; the more important variable is not geography but whether a company can keep converting science into non-dilutive cash via partners. That makes the current drawdown more attractive in outsourced picks-and-shovels than in therapeutic beta.

Key Decisions for Investors

• Go long VRDN on 1-3 month horizon if supply-chain de-risking accelerates into the next data window; the bull case is that non-exclusive supplier status becomes a recurring revenue stream with lower policy sensitivity than direct China exposure. Use a tight stop if U.S.-China licensing rhetoric escalates further.
• Add to PFE only as a relative-value expression, not outright alpha: pair long PFE vs short a basket of China-exposed innovator biotechs over the next 2-3 months. The edge is that global licensors with diversified pipelines can absorb regulatory noise better than firms reliant on one cross-border deal.
• Long a basket of China CDMOs / services versus short China biotech equities for 1-2 quarters. The trade benefits from deal flow shifting from ownership to outsourced execution, which supports utilization and pricing power even if headline sentiment stays weak.
• Buy call spreads on high-quality outsourced developers into ASCO, targeting a 4-8 week catalyst window. The risk/reward favors event-driven upside if data readouts improve conviction and investors rotate toward companies with real commercialization pathways rather than policy-encumbered narratives.
• Avoid initiating fresh longs in U.S.-listed China biotech ADRs until there is visibility on legislation; any relief rally is likely to be sold unless the proposed restrictions are narrowed. Use rallies to hedge or reduce exposure rather than chase.